Takeda Gets Serious About Regen Medicine With TiGenix Buy
Executive Summary
Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.
You may also be interested in...
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
M&A Analysis: January, Crisp Start To The Year
2018 kicked off with 17 medtech M&A deals in January, an increase from the 12 transactions recorded in the same period last year. The month also saw major medtech players reel in some significant acquisitions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.